• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

James R. Ramsey, Ph.D., President University of Louisville, Joins Advanced Cancer Therapeutics Board of Directors

Posted on: Wednesday, 24 September 2008, 09:00 CDT

Advanced Cancer Therapeutics, LLC (ACT) today announced that James R. Ramsey, Ph.D. has joined its board of directors. A frequent national speaker and writer on economic issues, Dr. Ramsey is the president of the University of Louisville.

"We are honored to have Dr. Ramsey join our board of directors," said Dale J. Boden, Chairman of the Board of ACT. "Dr. Ramsey brings a unique combination of economic and public policy experience which will be invaluable in guiding the Company as we continue to advance our pipeline of anti-cancer products closer to human clinical trials."

Dr. Ramsey has served as president of the University of Louisville since late 2002. During the previous 20 years, he held a variety of positions within the Commonwealth of Kentucky's public sector, including most recently, Interim Commissioner of the Office of the New Economy, Senior Policy Advisor/State Budget Director and Chief State Economist for the Commonwealth.

"I am pleased to join the ACT board at this exciting time," said Dr. Ramsey. "I look forward to contributing my experience to the development of the Company as it works to bring novel anti-cancer therapeutics to the patients who need them."

Dr. Ramsey earned his Ph.D. in Economics from the University of Kentucky.

About Advanced Cancer Therapeutics (ACT)

ACT is a biopharmaceutical company dedicated to advancing novel therapeutics for the prevention and treatment of cancer. Through its innovative partnership with the University of Louisville's James Graham Brown Cancer Center, ACT selects the most promising compounds from the Center's broad pipeline and brings those potential products through Phase I clinical development before seeking outlicensing opportunities. The Company currently has three compounds in preclinical development and expects to file an Investigational New Drug (IND) for its lead compound in 2009. For more information, please visit: www.advancedcancertherapeutics.com.

Source: Business Wire

More News in this Category